SCHEMBL4154288

SCHEMBL4154288

Cc1ccc(-c2nc(C)c(C=CC(=O)N(C)C)s2)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.43
TSHR P16473 1/20 0.43
RAB9A P51151 5/20 0.37
SMN1; SMN2 Q16637 5/20 0.37
ALDH1A1 P00352 4/20 0.37
KMT2A Q03164 2/20 0.37
NPC1 O15118 2/20 0.37
MEN1 O00255 1/20 0.37
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
LMNA P02545 3/20 0.36
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C19 P33261 1/20 0.36
MAPT P10636 3/20 0.35
ATM Q13315 1/20 0.35
KDM4E B2RXH2 2/20 0.35
GAA P10253 1/20 0.35
NR4A2 P43354 1/20 0.34
DYRK1A Q13627 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2412008 0.84 CYP1A2 (0.54) HSD17B10TSHRRAB9ASMN1; SMN2ALDH1A1
SCHEMBL4170787 0.76 CDC7 (0.49) RAB9ASMN1; SMN2ALDH1A1KMT2ANPC1
SCHEMBL4161874 0.75 HDAC3 (0.47) RAB9ASMN1; SMN2ALDH1A1KMT2ANPC1
SCHEMBL4167341 0.74 KDM4E (0.53) HSD17B10RAB9ASMN1; SMN2ALDH1A1KMT2A
SCHEMBL4164806 0.73 KDM4E (0.36) RAB9ASMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL4161913 0.73 CCNC (0.36) RAB9ASMN1; SMN2ALDH1A1KMT2ANPC1
SCHEMBL4154290 0.73 RAB9A (0.70) HSD17B10TSHRRAB9ASMN1; SMN2ALDH1A1
SCHEMBL2076088 0.72 NR4A2 (0.35) RAB9ASMN1; SMN2ALDH1A1CCNCCDK8
SCHEMBL15991053 0.71 MAPT (0.43) HSD17B10TSHRRAB9AALDH1A1KMT2A
SCHEMBL20894307 0.71 RAB9A (0.68) RAB9ASMN1; SMN2ALDH1A1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CDK2, CDK4, CDK20 HSD17B10 3232/4885TSHR 3510/4885RAB9A 2128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.